CD274 and neoplasm: The pCR rate was higher in patients with PD-L1-positive tumors in both treatment arms, the effect being statistically significant for tumor cell PD-L1 expression in the durvalumab arm and for immune cell PD-L1 expression in the placebo arm [72].